197 related articles for article (PubMed ID: 33898630)
1. Autologous antigen-presenting cells efficiently expand
Nakamura K; Yagyu S; Hirota S; Tomida A; Kondo M; Shigeura T; Hasegawa A; Tanaka M; Nakazawa Y
Mol Ther Methods Clin Dev; 2021 Jun; 21():315-324. PubMed ID: 33898630
[TBL] [Abstract][Full Text] [Related]
2.
Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
Front Immunol; 2022; 13():770132. PubMed ID: 35154098
[TBL] [Abstract][Full Text] [Related]
3. Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcoma.
Kubo H; Yagyu S; Nakamura K; Yamashima K; Tomida A; Kikuchi K; Iehara T; Nakazawa Y; Hosoi H
Mol Ther Oncolytics; 2021 Mar; 20():646-658. PubMed ID: 33816783
[TBL] [Abstract][Full Text] [Related]
4. Manufacturing NKG2D CAR-T cells with piggyBac transposon vectors and K562 artificial antigen-presenting cells.
Tay JCK; Wang J; Du Z; Ng YY; Li Z; Ren Y; Zhang C; Zhu J; Xu XH; Wang S
Mol Ther Methods Clin Dev; 2021 Jun; 21():107-120. PubMed ID: 33816644
[TBL] [Abstract][Full Text] [Related]
5. Differences in the phenotypes and transcriptomic signatures of chimeric antigen receptor T lymphocytes manufactured
Niu A; Zou J; Hu X; Zhang Z; Su L; Wang J; Lu X; Zhang W; Chen W; Zhang X
Front Immunol; 2023; 14():1068625. PubMed ID: 37228617
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in
Morita D; Nishio N; Saito S; Tanaka M; Kawashima N; Okuno Y; Suzuki S; Matsuda K; Maeda Y; Wilson MH; Dotti G; Rooney CM; Takahashi Y; Nakazawa Y
Mol Ther Methods Clin Dev; 2018 Mar; 8():131-140. PubMed ID: 29687032
[TBL] [Abstract][Full Text] [Related]
7. [Engineering memory-rich CAR-T cells by a piggyBac transposon system].
Yagyu S
Rinsho Ketsueki; 2023; 64(5):418-426. PubMed ID: 37271534
[TBL] [Abstract][Full Text] [Related]
8. Enzymatically produced piggyBac transposon vectors for efficient non-viral manufacturing of CD19-specific CAR T cells.
Kaštánková I; Štach M; Žižková H; Ptáčková P; Šmilauerová K; Mucha M; Šroller V; Otáhal P
Mol Ther Methods Clin Dev; 2021 Dec; 23():119-127. PubMed ID: 34631931
[TBL] [Abstract][Full Text] [Related]
9. Shortened ex vivo manufacturing time of EGFRvIII-specific chimeric antigen receptor (CAR) T cells reduces immune exhaustion and enhances antiglioma therapeutic function.
Caruso HG; Tanaka R; Liang J; Ling X; Sabbagh A; Henry VK; Collier TL; Heimberger AB
J Neurooncol; 2019 Dec; 145(3):429-439. PubMed ID: 31686330
[TBL] [Abstract][Full Text] [Related]
10. PiggyBac-engineered T cells expressing a glypican-3-specific chimeric antigen receptor show potent activities against hepatocellular carcinoma.
Wang P; Qin W; Liu T; Jiang D; Cui L; Liu X; Fang Y; Tang X; Jin H; Qian Q
Immunobiology; 2020 Jan; 225(1):151850. PubMed ID: 31522780
[TBL] [Abstract][Full Text] [Related]
11. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
12. Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials.
Ramanayake S; Bilmon I; Bishop D; Dubosq MC; Blyth E; Clancy L; Gottlieb D; Micklethwaite K
Cytotherapy; 2015 Sep; 17(9):1251-67. PubMed ID: 26212611
[TBL] [Abstract][Full Text] [Related]
13. CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo.
Chicaybam L; Abdo L; Carneiro M; Peixoto B; Viegas M; de Sousa P; Fornazin MC; Spago MC; Albertoni Laranjeira AB; de Campos-Lima PO; Nowill A; Barros LRC; Bonamino MH
Hum Gene Ther; 2019 Apr; 30(4):511-522. PubMed ID: 30793967
[TBL] [Abstract][Full Text] [Related]
14. A new approach to CAR T-cell gene engineering and cultivation using piggyBac transposon in the presence of IL-4, IL-7 and IL-21.
Ptáčková P; Musil J; Štach M; Lesný P; Němečková Š; Král V; Fábry M; Otáhal P
Cytotherapy; 2018 Apr; 20(4):507-520. PubMed ID: 29475789
[TBL] [Abstract][Full Text] [Related]
15. Autologous non-human primate model for safety assessment of
Morokawa H; Yagyu S; Hasegawa A; Tanaka M; Saito S; Mochizuki H; Sakamoto K; Shimoi A; Nakazawa Y
Clin Transl Immunology; 2020; 9(11):e1207. PubMed ID: 33251009
[TBL] [Abstract][Full Text] [Related]
16. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ
Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873
[TBL] [Abstract][Full Text] [Related]
17. Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors.
Chang ZL; Silver PA; Chen YY
J Transl Med; 2015 May; 13():161. PubMed ID: 25990251
[TBL] [Abstract][Full Text] [Related]
18. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
[No Abstract] [Full Text] [Related]
19. Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo.
Song Y; Tong C; Wang Y; Gao Y; Dai H; Guo Y; Zhao X; Wang Y; Wang Z; Han W; Chen L
Protein Cell; 2018 Oct; 9(10):867-878. PubMed ID: 28284008
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo.
Liao Q; Mao Y; He H; Ding X; Zhang X; Xu J
Biomark Res; 2020 Nov; 8(1):57. PubMed ID: 33292688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
